Related Experiment Video

Updated: Jul 19, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

Mahvash Zakikhani1, Ryan Dowling, I George Fantus

  • 1Department of Oncology, McGill University, Montreal, Quebec, Canada.

Cancer Research
|October 26, 2006
PubMed

Insights

Metformin, a diabetes drug, inhibits epithelial cell growth by activating AMP kinase pathway. This mechanism may explain metformin's potential anti-cancer effects, suggesting new therapeutic avenues.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Metformin is a common type 2 diabetes medication known to lower blood glucose and reduce hyperinsulinemia.
  • Insulin and insulin-like growth factors can stimulate the proliferation of normal and cancerous cells.
  • Population studies suggest metformin use may correlate with reduced cancer incidence and improved prognosis.

Purpose of the Study:

  • To investigate the effect of metformin on epithelial cell growth.
  • To determine if metformin acts as a growth inhibitor or insulin sensitizer for epithelial cells.
  • To elucidate the molecular mechanisms underlying metformin's effects on cell proliferation.

Main Methods:

  • Investigated metformin's effect on epithelial cell growth in vitro.
  • Utilized small interfering RNA (siRNA) against AMP kinase to assess its role in metformin's effects.
  • Measured activation of mammalian target of rapamycin (mTOR) and S6 kinase pathways.
  • Assessed global mRNA translation rates.

Main Results:

  • Metformin demonstrated a growth inhibitory effect on epithelial cells, contrary to an insulin-sensitizing role.
  • AMP kinase pathway activation was essential for metformin-induced growth inhibition, as confirmed by siRNA experiments.
  • Metformin treatment led to decreased activation of mTOR and S6 kinase.
  • A general reduction in mRNA translation was observed in metformin-treated cells.

Conclusions:

  • Metformin inhibits epithelial cell growth via activation of the AMP kinase pathway.
  • This mechanism provides a potential explanation for the observed antineoplastic effects of metformin in population studies.
  • Further research into AMP kinase activators for cancer prevention and treatment is warranted.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...